Pérez-Guzmán C, Gutiérrez-Mendoza I, Serna-Vela FJ, Góngora OJ

Idioma: Español
Referencias bibliográficas: 33
Paginas: 209-212
Archivo PDF: 67.29 Kb.

FRAGMENTO

La tuberculosis (TB) es en la actualidad una de las principales causas de muerte a nivel mundial afectando principalmente a los países en vías de desarrollo. Es responsable de 2 millones de muertes en todo el mundo y se presentan 8 millones de casos nuevos cada año a nivel mundial.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-899.

2. Chakrabarti B, Davies PD. Key issues in multidrug-resistant tuberculosis. Future Microbiol 2007;2:51-61.

3. 3. Crofton J, Chaulet P, Maher D. Guidelines for the Management of Drug-resistant Tuberculosis. Geneva, Switzerland. World Health Organization publication 1997. Geneva, Switzerland. WHO/TB 97.220.

4. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002;325:1282-1286.

5. Ditah IC, Reacher M, Palmer C, et ál. Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective. Thorax 2008;63:440-446.

6. Drobniewski FA, Balabanova YM. The diagnosis and management of multiple-drug-resistant-tuberculosis at the beginning of the new millenium. Int J Infect Dis 2002;6 Suppl 1:S21-S31.

7. Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin Chest Med 1989:10:341-353.

8. Rieder HL. Interventions for tuberculosis control and elimination. Paris, France: International Union Against Tuberculosis and Lung Disease;2002.p.15-93.

9. Schluger NW, Harkin TJ, Rom WN. Principles of therapy of tuberculosis in the modern era. In: Rom WN, Garay S, editors. Tuberculosis. New York, NY: Little, Brown and Company;1996.p.751-761.

10. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123(4 Pt 1):367-371.

11. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4:796-806.

12. Norma Oficial Mexicana. Guía para la Atención de Pacientes con Tuberculosis Multifarmacorresistente. Secretaría de Salud. México, DF:SSA;2004.

13. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003.313. World Health Organization-Geneva;2003.

14. Rich ML, Socci AR, Mitnick CD, et ál. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 2006;10:290-296.

15. American Thoracic Society Documents. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662.

16. Caminero JA, de March P. Statements of ATS, CDC, and IDSA on treatment of tuberculosis. Am J Respir Crit Care Med 2004;169:316-317.

17. Espinal MA, Kim SJ, Suárez PG, et ál. Standard short-course of chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-2545.

18. García-García ML, Mayar-Maya ME, Ferreyra-Reyes L, Palacios-Martínez M, Álvarez-García C, Valdespino-Gómez JL. Efficacy and efficiency of antitubercular treatment in health jurisdictions of Morelos. Salud Pública Mex 1998;40:421-429.

19. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999;160:587-593.

20. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-532.

21. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2:877-884.

22. Dalcolmo MP, Fortes A, Melo FF, et ál. Outcomes of multidrug resistant tuberculosis (MDR TB) treatment in Brazil-Partial results- as of April 1998. J Pneumol 1999;25:70-77.

23. Pérez-Guzmán C, Vargas MH, Martínez-Rossier LA, Torres-Cruz A, Villarreal-Velarde H. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2002;6:1102-1109.

24. Hersi A, Elwood K, Cowie R, Kunimoto D, Long R. Multidrug-resistant tuberculosis in Alberta and British Columbia, 1989 to 1998. Can Respir J 1999;6:155-160.

25. Ollé-Goig JE, Sandy R. Outcomes of individualized treatment for multidrug-resistant tuberculosis before DOTS-plus. Int J Tuberc Lung Dis 2005;9:765-770.

26. Thomas A, Ramachandran R, Rehaman F, et ál. Management of multi-drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian J Tuberc 2007;54:117-124.

27. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardized regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004;8:560-567.

28. Yew WW, Chan CK, Chau CH, et ál. Outcomes of patients with multi-drug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-751.

29. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-2099.

30. Ntziora F, Falagas ME. Linezolid for the treatment of patients with atypical mycobacterial infection. A systematic review. Int J Tuberc Lung Dis 2007;11:606-611.

31. Ohkado A, Aguiman L, Adlawan S, et ál. Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines. Int J Tuberc Lung Dis 2006;10:283-289.

32. Panova LV, Ovsiankina ES. Treatment and outcomes of tuberculosis with multi-drug resistance of MBT in children and adolescents. Probl Tuberk Bolezn Legk 2007;(5):20-22.

33. Garifullin ZR. Optimization of surgical treatment for drug-resistant respiratory tuberculosis. Probl Tuberk Bolezn Legk 2007;(6):9-13.